About Braeburn
Braeburn is a company based in Philadelphia (United States) founded in 2012. Braeburn has raised $110 million across 2 funding rounds from investors including New Leaf Venture Partners, RA Capital and Wellington. Braeburn offers products and services including OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs. Braeburn operates in a competitive market with competitors including Avidity Biosciences, Univercells, Indivior, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Philadelphia, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website braeburnrx.com
- Social LinkedIn X Instagram
- Legal Name Braeburn Inc
- Total Equity Funding$110M (USD)
in 2 rounds
- Latest Funding Round$110M (USD), Debt – Conventional
Jan 2018
- InvestorsNew Leaf Venture Partners
& 6 more
Products & Services of Braeburn
Braeburn offers a comprehensive portfolio of products and services, including OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs.
Products for managing opioid use disorder and supporting recovery.
Series featuring stories to reduce stigma around addiction.
Programs partnering with organizations for opioid crisis response.
Funding Insights of Braeburn
Braeburn has successfully raised a total of $110M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $110 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110M
- Total Rounds 2
- Last Round Debt – Conventional — $110M
- First Round $110M
(Jan 2018)
- Investors Count 7
All 2 funding rounds of Braeburn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $110M | Debt – Conventional | – | – | |
| Jan 2018 | $110M | Series D | – | – | – |
7 investors in total: 7 institutional.
Investors in Braeburn
Braeburn has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, RA Capital and Wellington.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Apple Tree Partners is engaged in life sciences venture capital. | – | appletreepartners.com | - | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Investments are made in healthcare companies to drive growth. | – | avistahealthcare.com | New York, United States |
Investor details for Braeburn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Braeburn
88 people are tracked at Braeburn (30 in leadership, 6 in board & advisors, 52 in team).
| Name | Role | Group |
|---|---|---|
Mike Derkacz | CEO | Leadership |
Wendy Miller | Director, Market Research | Leadership |
James DeMicco | Director, Medical Affairs | Leadership |
Vikki Lovvoll | Vice President Business Operations | Leadership |
Ted Buckley | VP, Government Affairs | Leadership |
Todd Gramins | Regional Director, Northeast | Leadership |
Edward R. | Senior Regional Sales Director | Leadership |
Norm Curry | Vice President Of Sales | Leadership |
Louis Ricigliano | CFO | Leadership |
Natasha Dowd | National Account Director | Leadership |
Craig Patrizio | Director Of Technical Operations | Leadership |
Shawn Elms | Director of Field Medical Affairs | Leadership |
Nancy Shanfelt | Senior Director Sales Operations | Leadership |
Judy Cohen | Vice President Manufacturing Operations | Leadership |
Natalie Budilovsky-Kelley Pharm.D. | Head Of Medical Affairs | Leadership |
Tom Connolly | Executive Vice President, Head Of Sales & Marketing | Leadership |
Jorge Vasquez | Senior Director, Strategic Project Management | Leadership |
Laura Hoffman | Director of Quality Operations | Leadership |
Renata Rauth, SHRM-SCP | Senior Director Human Resources | Leadership |
Joshua Cohen | Chief Medical Officer | Leadership |
68 more people are available in the full profile.
Complete people profiles for Braeburn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Braeburn
3 dated milestones of Braeburn across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Braeburn is founded.
- Funding First funding round of $110.0M.
- Funding Latest funding round, Debt – Conventional, of $110.0M.
Competitors of Braeburn
Braeburn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Indivior, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Braeburn
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Braeburn
The website of Braeburn (braeburnrx.com) receives about 9.5K visits a month.
- Monthly visits9.5K
▲ 42.8% vs previous month
Latest news on Braeburn
Complete news archive for Braeburn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Braeburn
10 companies that operate in the same segment as Braeburn (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Braeburn
Braeburn was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Braeburn is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Mike Derkacz is the current CEO of Braeburn.
Braeburn is a funded company, having raised a total of $110M across 2 funding rounds to date. The company's 1st funding round was a Series D of $110M, raised on Jan 2018.
Braeburn was founded in 2012 in Philadelphia, United States, within the biotechnology sector. Implantable and injectable formulations for treating opioid addiction and chronic pain are developed. The lead product, Probufine, a buprenorphine implant, has been approved by the FDA for opioid dependence. CAM2038 undergoes NDA refiling for opioid dependence and is in phase 3 trials for pain management, delivered subcutaneously via the proprietary FluidCrystal system.
Braeburn's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Braeburn offers OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs.
Braeburn has 7 investors. Key investors include New Leaf Venture Partners, RA Capital, Wellington, Deerfield, and Rock Springs Capital.
Braeburn operates through Braeburn Inc.